17 May 2026VideosAmericasRolando Medina, Choate | MJ Edwards, Gilead Sciences | Manja Epping, Heuking | Lillian Hiett, Takeda Pharmaceuticals
WATCH: Navigating the regulatory-IP nexus—maximizing exclusivity in an evolving policy landscape
The intersection of regulatory strategy and intellectual property protection has become critical to maintaining market exclusivity. This panel examines how life sciences companies can adapt their IP strategies in response to shifting FDA guidance, biosimilar challenges, and evolving agency priorities.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.